Nanotechnology approaches for inhalation treatment of lung diseases.

The skin barrier function has been attributed to the stratum corneum and represents a major challenge in clinical practice pertaining to cutaneous administration of drugs. Despite this, a large number of bioactive compounds have been successfully administered via cutaneous administration because of advances in the design of topical and transdermal formulations. In vitro and in vivo evaluations of these novel drug delivery systems are necessary to characterize their quality and efficacy. This review covers the most well-known methods for assessing the cutaneous absorption of drugs as an auxiliary tool for pharmaceutical formulation scientists in the design of drug delivery systems. In vitro methods as skin permeation assays using Franz-type diffusion cells, cutaneous retention and tape-stripping methods to study the cutaneous penetration of drugs, and in vivo evaluations as pre-clinical pharmacokinetic studies in animal models are discussed. Alternative approaches to cutaneous microdialysis are also covered. Recent advances in research on skin absorption of drugs and the effect of skin absorption enhancers, as investigated using confocal laser scanning microscopy, Raman confocal microscopy, and attenuated total reflectance Fourier-transform infrared spectroscopy, are reviewed.

https://www.revistas.usp.br/bjps/article/download/128351/125223

Evaluation of skin absorption of drugs from topical and transdermal formulations

Hierarchical targeted hepatocyte mitochondrial multifunctional chitosan nanoparticles for anticancer drug delivery.

Recently, advances in pharmaceutical research is focused on new delivery systems utilizing new devices to achieve modification of delivery time, targeting, as well as improve the in vivo solubility and hence bioavailability of poorly soluble drugs. Lipid based drug delivery systems (LDDS) consists of diverse group of formulations, each consisting of varying functional and structural properties that are amenable to modifications achieved by varying the composition of lipid excipients and other additives. LDDS has evolved, overtime, from micro- to nano-scale enhancing the efficacy and therapeutic application of these systems. LDDS are accepted, proven, commercially viable strategies for formulating challenging pharmaceutical molecules and can be tailored to meet a wide range of product requirements. Generally, most lipid drug delivery systems used as drug carriers have high stability, high carrier capacity, feasibility of incorporating both hydrophilic and hydrophobic substances and feasibility of variable routes of administration, including oral, topical, parenteral and pulmonary routes. LDDS can also be designed to allow modified drug release from matrices. LDDS could be broadly grouped into four: solid lipid particulate dosage forms, emulsion based systems, solid lipid tablets, and vesicular systems. Modifications from these four types include: lipospheres, solid lipid nanoparticles (SLNs), nano structured lipid carriers (NLC), lipid drug conjugate nanoparticles (LDC), self emulsifying formulations (SEFs), pickering emulsions, dry emulsions, micro and nano-emulsions, solidified reverse micellar solution (SRMS) based tablets, liposomes, herbosomes, cryptosomes and transferosomes amongst others. This work exhaustively reviewed the advances in LDDS and also drew comparison between the different types based on history, methods of manufacture, applications, advantages and disadvantages.

	Key words: Cryptosomes, lipospheres, lipoplexes, solid lipid tablets, pharmacosomes, virosomes, vesosomes.

/pdf/lipid-based-drug-delivery-systems-ldds-recent-advances-and-4kmafc4yx9.pdf

Lipid-based drug delivery systems (LDDS): Recent advances and applications of lipids in drug delivery

The development of cellular resistance to platinum-based chemotherapies is often associated with reduced intracellular platinum concentrations. In some models, this reduction is due to abnormal membrane protein trafficking, resulting in reduced uptake by transporters at the cell surface. Given the central role of platinum drugs in the clinic, it is critical to overcome cisplatin resistance by bypassing the plasma membrane barrier to significantly increase the intracellular cisplatin concentration enough to inhibit the proliferation of cisplatin-resistant cells. Therefore, rational design of appropriate nanoscale drug delivery platforms (nDDPs) loaded with cisplatin or other platinum analogues as payloads is a possible strategy to solve this problem. This review will focus on the known mechanism of membrane trafficking in cisplatin-resistant cells and the development and employment of nDDPs to improve cell uptake of cisplatin.

/pdf/nanoscale-drug-delivery-platforms-overcome-platinum-based-4uoxcez3u6.pdf

Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking.

A simple and low-cost HPLC method with UV absorbance detection was developed and validated to simultaneously determine strychnine and brucine, the most abundant alkaloids in the processed Semen Strychni, in rat tissues (kidney, liver, spleen, lung, heart, stomach, small intestine, brain and plasma). The tissue samples were treated with a simple liquid-liquid extraction prior to HPLC. The LOQs were in the range of 0.039-0.050 µg/ml for different tissue or plasma samples. The extraction recoveries varied from 71.63 to 98.79%. The linear range was 0.05-2 µg/ml with correlation coefficient of over 0.991. The intra- and inter-day precision was less than 15%. Then the method was used to measure the tissue distribution of strychnine and brucine after intravenous administration of 1 mg/kg crude alkaloids fraction (CAF) extracted from the processed Semen Strychni. The results revealed that strychnine and brucine possessed similar tissue distribution characterization. The highest level was observed in kidney, while the lowest level was found in brain. It was indicated that kidney might be the primary excretion organ of prototype strychnine and brucine. It was also deduced that strychnine and brucine had difficulty in crossing the blood-brain barrier. Furthermore, no long-term accumulation of strychnine and brucine was found in rat tissues.

/pdf/hplc-determination-of-strychnine-and-brucine-in-rat-tissues-3rqhmv0rq7.pdf

Yun Fang

Papers

HPLC determination of strychnine and brucine in rat tissues and the distribution study of processed semen strychni.

Pharmacokinetics of brucine after intravenous and oral administration to rats.

Evaluation of the pharmacodynamics and pharmacokinetics of brucine following transdermal administration

Pharmacokinetics of homoplantaginin in rats following intravenous, peritoneal injection and oral administration

Pharmacokinetics, tissue distribution, and the lactone/carboxylate equilibrium of hydroxycamptothecin delivered via aerosol in mice.